RUNX2 and breast cancer: EXOs derived from adipose mesenchymal stem cells deliver miR-218 to breast cancer cells, where miR-218 can inhibit angiogenesis and EMT by targeting Runx2 and Rictor, preventing breast cancer progression [80].